GSK and Flamel entered into licensing agreement for Flamel’s Micropump® Technology useful for both pediatrics and geriatrics. The technology uses microparticles that extends the time of action of small molecules. The deal could be worth up to US$45 M to Flamel if specific milestones and sales targets are met.